

### Remarks

In the Office Action, the Examiner noted that claims 1, 2, 6-36, 40-55, 58 and 59 are pending in the application; claims 54-57 are withdrawn from consideration; claims 1, 2, 6-9, 40, 53, 58 and 59 are rejected; and claims 10-36 and 41-52 are objected to.


By this amendment, claims 1, 7 and 9 have been amended. Thus, claims 1, 2, 6-36, 40-55, 58 and 59 are pending in the application are pending in the application. No new subject matter has been inserted through these amendments. All of the amendments are fully supported by the specification.

More specifically, claims 1, 7 and 9 have been amended to limit one of the definitions of  $R^1$  and  $R^2$  together forms to "polycyclic aromatic ring" from "monocyclic or polycyclic aromatic." As a result all of the specific "monocyclic aromatic" moieties within the definition of  $R^1$  and  $R^2$  have been deleted from claims 7 and 9. The Examiner's rejections are respectfully traversed below.

### ***Rejection Under 35 U.S.C. § 102(e)***

Claims 1, 2, 6-9, 40, 53, 58 and 59 stand rejected under 35 U.S.C. 102(e) as being anticipated by Auerbach et al. (US 6,875,780).

In particular, Examiner alleges that "Auerbach discloses (Col. 75, l. 1-15) the following compound with the allowed variable assignments shown:



$R^1, R^2$  (together) = monocyclic aryl

The Examiner considers  $R^1$  and  $R^2$  to represent the same group and together represent an aryl group" Office Action at page 3.

Although Applicants respectfully disagree with Examiner's interpretation of instant claim 1 in light of Auerbach et al's disclosure, solely for the purpose of expediting the prosecution of the instant case, it is submitted that independent claim 1, as amended, recites R<sup>1</sup> and R<sup>2</sup> together forms only "polycyclic aromatic ring," thus rendering this rejection moot. Further, only two other dependent claims 7 and 9 which recite the definitions of R<sup>1</sup> and R<sup>2</sup> have similarly been amended. Therefore, it is respectfully submitted that none of the claims 1, 2, 6-9, 40, 53, 58 and 59 anticipates Auerbach et al. Accordingly, withdrawal of rejection as to claims 1, 2, 6-9, 40, 53, 58 and 59 is respectfully requested.

#### ***Claim Objections***

Claims 10-36 and 41-52 stand objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

However, as noted above, it is believed that independent claim 1, as amended, overcomes all of the outstanding rejections as specifically articulated herein. Accordingly, the above objection as to claims 10-36 and 41-52, which depend directly or indirectly upon claim 1, as amended, is rendered moot. Thus, withdrawal of objection as to claims 10-36 and 41-52 is respectfully requested.

#### ***Allowable Subject Matter***

Applicants acknowledge with much appreciation Examiner's indication of allowability of claims 10-36 and 41-52. For the reasons advanced above, it is also believed that claims 1, 2, 6-9, 40, 53, 58 and 59, as amended, are also in condition for allowance and such as action is earnestly solicited.

#### ***Rejoinder of Method claims 54 and 55***

The Examiner has further noted that the method claims 54 and 55 will be considered for compliance with 35 U.S.C. 112, 102 and 103. However, as already noted

above, withdrawn claims 54 and 55 depend directly upon independent claim 1 incorporating all of the limitations of claim 1, and further recite certain methods of treatments which are believed to be in condition for allowance. Therefore, it is respectfully submitted that claims 54 and 55 be rejoined and allowed with the rest of the pending claims.

### ***Conclusions***

In view of the above Remarks, it is respectfully submitted that claims 1, 2, 6-36, 40-55, 58 and 59 are now in condition for allowance and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

Applicants believe there are no fees due for this Rule 116 Amendment. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. Deposit Account No. **50-3221** for Dr. Reddy's Laboratories, Inc., Bridgewater, NJ. Please credit any overpayment to Deposit Account No. **50-3221**.

Respectfully submitted,

April 5, 2011

/Balaram Gupta/  
Balaram Gupta, Ph. D., J. D.  
Registration No. 40,009  
Attorney for Applicants

**Dr. Reddy's Laboratories, Inc.**  
200 Somerset Corporate Blvd. 7th Floor  
Bridgewater, NJ 08807  
Tel. No. (908) 203-6508  
Fax: (908) 203-6515  
[bgupta@drreddys.com](mailto:bgupta@drreddys.com)